

# Benjamin L Handen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2179177/publications.pdf>

Version: 2024-02-01

119  
papers

4,106  
citations

117571

34  
h-index

128225

60  
g-index

123  
all docs

123  
docs citations

123  
times ranked

2843  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Impact of the Comorbidity of ASD and ADHD on Social Impairment. <i>Journal of Autism and Developmental Disorders</i> , 2022, 52, 2512-2522.	1.7	18
2	PET imaging in Down syndrome and Alzheimer's disease. , 2022, , 173-192.		1
3	White matter microstructure associations to amyloid burden in adults with Down syndrome. <i>NeuroImage: Clinical</i> , 2022, 33, 102908.	1.4	1
4	Cortical atrophy and amyloid and tau deposition in Down syndrome: A longitudinal study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, e12288.	1.2	2
5	Role of tau deposition in early cognitive decline in Down syndrome. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, e12256.	1.2	6
6	Impact of the COVID-19 pandemic on daily life, mood, and behavior of adults with Down syndrome. <i>Disability and Health Journal</i> , 2022, 15, 101278.	1.6	12
7	Conducting clinical trials in persons with Down syndrome: summary from the NIH INCLUDE Down syndrome clinical trials readiness working group. <i>Journal of Neurodevelopmental Disorders</i> , 2022, 14, 22.	1.5	13
8	Support vector machine learning and diffusion-derived structural networks predict amyloid quantity and cognition in adults with Down's syndrome. <i>Neurobiology of Aging</i> , 2022, 115, 112-121.	1.5	2
9	Joint label fusion brain atlases for dementia research in Down syndrome. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, .	1.2	1
10	Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers. <i>JAMA Neurology</i> , 2022, 79, 797.	4.5	17
11	Plasma Total-Tau and Neurofilament Light Chain as Diagnostic Biomarkers of Alzheimer's Disease Dementia and Mild Cognitive Impairment in Adults with Down Syndrome. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 671-681.	1.2	23
12	Neurofibrillary tau depositions emerge with subthreshold cerebral beta-amyloidosis in down syndrome. <i>NeuroImage: Clinical</i> , 2021, 31, 102740.	1.4	9
13	PET measurement of longitudinal amyloid load identifies the earliest stages of amyloid-beta accumulation during Alzheimer's disease progression in Down syndrome. <i>NeuroImage</i> , 2021, 228, 117728.	2.1	15
14	White matter microstructure associations with episodic memory in adults with Down syndrome: a tract-based spatial statistics study. <i>Journal of Neurodevelopmental Disorders</i> , 2021, 13, 17.	1.5	9
15	Postmortem Neocortical 3H-PiB Binding and Levels of Unmodified and Pyroglutamate A $\beta$ 2 in Down Syndrome and Sporadic Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 728739.	1.7	2
16	Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study. <i>Lancet Neurology</i> , The, 2021, 20, 615-626.	4.9	26
17	Acute Regression in Down Syndrome. <i>Brain Sciences</i> , 2021, 11, 1109.	1.1	3
18	Physical activity and cognitive and imaging biomarkers of Alzheimer's disease in down syndrome. <i>Neurobiology of Aging</i> , 2021, 107, 118-127.	1.5	17

#	ARTICLE	IF	CITATIONS
19	Sleep and White Matter in Adults with Down Syndrome. <i>Brain Sciences</i> , 2021, 11, 1322.	1.1	4
20	Physical activity, cognitive decline and biomarkers of Alzheimer's disease in adults with Down syndrome. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
21	Longitudinal PET imaging identifies earliest stages of A $\beta$ accumulation in Down syndrome. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
22	Associations between cognition, A $\beta$ , and tau in adults with Down syndrome. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
23	Amyloid and tau deposition influences cognitive decline in Down syndrome. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
24	Elevated neurofibrillary tau levels emerge with subthreshold A $\beta$ accumulation in Down syndrome. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
25	The SOFIA Study: Negative Multi-center Study of Low Dose Fluoxetine on Repetitive Behaviors in Children and Adolescents with Autistic Disorder. <i>Journal of Autism and Developmental Disorders</i> , 2020, 50, 3233-3244.	1.7	33
26	The Alzheimer's Biomarker Consortium's Down Syndrome: Rationale and methodology. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12065.	1.2	49
27	Diffusion structural network metrics as a predictor for Alzheimer's disease diagnosis in Down syndrome using support vector machine classification. <i>Alzheimer's and Dementia</i> , 2020, 16, e040261.	0.4	0
28	White matter microstructure and episodic memory in adults with down syndrome: A Tract-Based Spatial Statistics (TBSS) Study. <i>Alzheimer's and Dementia</i> , 2020, 16, e044673.	0.4	1
29	Predicting the time to tau onset in Down syndrome using amyloid chronicity. <i>Alzheimer's and Dementia</i> , 2020, 16, e046060.	0.4	1
30	Amyloid accumulation in Down syndrome measured with amyloid load. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12020.	1.2	19
31	Association of sleep with cognition and beta amyloid accumulation in adults with Down syndrome. <i>Neurobiology of Aging</i> , 2020, 93, 44-51.	1.5	24
32	The AT(N) framework for Alzheimer's disease in adults with Down syndrome. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12062.	1.2	12
33	Cognitive indicators of transition to preclinical and prodromal stages of Alzheimer's disease in Down syndrome. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12096.	1.2	20
34	Leisure activity in middle-aged adults with Down syndrome: Initiators, social partners, settings and barriers. <i>Journal of Applied Research in Intellectual Disabilities</i> , 2020, 33, 865-875.	1.3	15
35	Patterns of glucose hypometabolism in Down syndrome resemble sporadic Alzheimer's disease except for the putamen. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12138.	1.2	7
36	Neuropathological correlates of amyloid PET imaging in Down syndrome. <i>Developmental Neurobiology</i> , 2019, 79, 750-766.	1.5	34

#	ARTICLE	IF	CITATIONS
37	Selective Serotonin Reuptake Inhibitor Monotherapy for Anxiety Disorders in Children and Adolescents with Autism Spectrum Disorder: A Chart Review. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2019, 29, 705-711.	0.7	9
38	Assessing general cognitive and adaptive abilities in adults with Down syndrome: a systematic review. <i>Journal of Neurodevelopmental Disorders</i> , 2019, 11, 20.	1.5	26
39	Parent-child interaction therapy (PCIT) in young children with autism spectrum disorder. <i>Child and Family Behavior Therapy</i> , 2019, 41, 201-220.	0.5	31
40	Pharmacogenetics of Metformin for Medication-Induced Weight Gain in Autism Spectrum Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2019, 29, 448-455.	0.7	5
41	Leisure Activity, Brain Amyloid, and Episodic Memory in Adults with Down Syndrome. <i>Developmental Neurobiology</i> , 2019, 79, 738-749.	1.5	14
42	Longitudinal trajectories of amyloid deposition, cortical thickness, and tau in Down syndrome: A deep phenotyping case report. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 654-658.	1.2	13
43	ICAD03: SPATIAL ASSOCIATIONS OF A $\beta$ 2 WITH TAU DEPOSITION IN DOWN SYNDROME. <i>Alzheimer's and Dementia</i> , 2019, 15, P11.	0.4	0
44	ICAD04: SLEEP, COGNITION, AND A $\beta$ 2 IN ADULTS WITH DOWN SYNDROME. <i>Alzheimer's and Dementia</i> , 2019, 15, P12.	0.4	1
45	ICAD02: ASSOCIATIONS BETWEEN A $\beta$ 2 AND TAU IN ADULTS WITH DOWN SYNDROME. <i>Alzheimer's and Dementia</i> , 2019, 15, P11.	0.4	0
46	ICAD01: ASSESSMENT OF LONGITUDINAL AMYLOID LOAD CHANGE IN DOWN SYNDROME. <i>Alzheimer's and Dementia</i> , 2019, 15, P10.	0.4	0
47	An exploration of concomitant psychiatric disorders in children with autism spectrum disorder. <i>Comprehensive Psychiatry</i> , 2019, 88, 57-64.	1.5	72
48	Comparison of longitudinal A $\beta$ 2 in nondemented elderly and Down syndrome. <i>Neurobiology of Aging</i> , 2019, 73, 171-176.	1.5	13
49	Factors associated with DSM-5 severity level ratings for autism spectrum disorder. <i>Autism</i> , 2019, 23, 468-476.	2.4	23
50	Testing Genetic Modifiers of Behavior and Response to Atomoxetine in Autism Spectrum Disorder with ADHD. <i>Journal of Developmental and Physical Disabilities</i> , 2018, 30, 355-371.	1.0	11
51	A 1.5-Year Follow-Up of Parent Training and Atomoxetine for Attention-Deficit/Hyperactivity Disorder Symptoms and Noncompliant/Disruptive Behavior in Autism. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2018, 28, 322-330.	0.7	11
52	Effects of Metformin on Spatial and Verbal Memory in Children with ASD and Overweight Associated with Atypical Antipsychotic Use. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2018, 28, 266-273.	0.7	8
53	Risk Factors for Self-injurious Behavior in an Inpatient Psychiatric Sample of Children with Autism Spectrum Disorder: A Naturalistic Observation Study. <i>Journal of Autism and Developmental Disorders</i> , 2018, 48, 3678-3688.	1.7	17
54	Early striatal amyloid deposition distinguishes Down syndrome and autosomal dominant Alzheimer's disease from late-onset amyloid deposition. <i>Alzheimer's and Dementia</i> , 2018, 14, 743-750.	0.4	51

#	ARTICLE	IF	CITATIONS
55	Atomoxetine, Parent Training, and Their Effects on Sleep in Youth with Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2018, 28, 130-135.	0.7	15
56	Parent Stress in a Randomized Clinical Trial of Atomoxetine and Parent Training for Children with Autism Spectrum Disorder. <i>Journal of Autism and Developmental Disorders</i> , 2018, 48, 980-987.	1.7	12
57	F5â€01â€03: LONGITUDINAL AMYLOID AND CROSSâ€SECTIONAL TAU PET IN DOWNâ€SYNDROME. <i>Alzheimer's and Dementia</i> , 2018, 14, P1625.	0.4	0
58	P1â€421: COMPARISON OF STRIATAL LONGITUDINAL CHANGES IN AMYLOID DEPOSITION IN NONâ€DEMENTED ELDERLY AND DOWN SYNDROME. <i>Alzheimer's and Dementia</i> , 2018, 14, P467.	0.4	0
59	ICâ€Pâ€004: AMYLOID BURDEN AND CORTICAL ATROPHY IN NONâ€DEMENTED DOWN SYNDROME. <i>Alzheimer's and Dementia</i> , 2018, 14, P16.	0.4	0
60	F5â€01â€04: COGNITIVE CORRELATES OF AMYLOID AND TAU PET IN DOWN SYNDROME. <i>Alzheimer's and Dementia</i> , 2018, 14, P1626.	0.4	0
61	P1â€445: AMYLOID BURDEN AND CORTICAL ATROPHY IN NONâ€DEMENTED DOWN SYNDROME. <i>Alzheimer's and Dementia</i> , 2018, 14, P484.	0.4	0
62	Dr. Handen etâ€Al. Reply. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2018, 57, 793-795.	0.3	0
63	The use of Centiloids for applying [ <sup>11</sup> C]PiB classification cutoffs across regionâ€ofâ€interest delineation methods. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 332-339.	1.2	22
64	A Prospective Study of the Concordance of DSM-IV and DSM-5 Diagnostic Criteria for Autism Spectrum Disorder. <i>Journal of Autism and Developmental Disorders</i> , 2017, 47, 2783-2794.	1.7	36
65	Adverse Events of Atomoxetine in a Double-Blind Placebo-Controlled Study in Children with Autism. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2017, 27, 708-714.	0.7	13
66	A Randomized, Placebo-Controlled Trial of Metformin for the Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorder: Open-Label Extension. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2017, 56, 849-856.e6.	0.3	39
67	Cognitive decline and brain amyloid- $\beta$ accumulation across 3 years in adults with Down syndrome. <i>Neurobiology of Aging</i> , 2017, 58, 68-76.	1.5	59
68	Caregiver Satisfaction with a Multisite Trial of Atomoxetine and Parent Training for Attention-Deficit/Hyperactivity Disorder and Behavioral Noncompliance in Children with Autism Spectrum Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2016, 26, 807-814.	0.7	4
69	Atomoxetine and Parent Training for Children With Autism and Attention-Deficit/Hyperactivity Disorder: A 24-Week Extension Study. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2016, 55, 868-876.e2.	0.3	30
70	Metformin for Treatment of Overweight Induced by Atypical Antipsychotic Medication in Young People With Autism Spectrum Disorder. <i>JAMA Psychiatry</i> , 2016, 73, 928.	6.0	94
71	The effects of normal aging on amyloidâ€ $\beta$ deposition in nondemented adults with Down syndrome as imaged by carbon 11â€labeled Pittsburgh compound B. <i>Alzheimer's and Dementia</i> , 2016, 12, 380-390.	0.4	65
72	Quetiapine in children and adolescents with subaverage IQ. <i>Journal of Pediatric Neurology</i> , 2015, 03, 035-039.	0.0	2

#	ARTICLE	IF	CITATIONS
73	Effect of Parent Training vs Parent Education on Behavioral Problems in Children With Autism Spectrum Disorder. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1524.	3.8	290
74	Atomoxetine, Parent Training, and Their Combination in Children With Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2015, 54, 905-915.	0.3	107
75	A review of atomoxetine effects in young people with developmental disabilities. <i>Research in Developmental Disabilities</i> , 2014, 35, 1412-1424.	1.2	40
76	Cognitive functioning in relation to brain amyloid- $\beta$ in healthy adults with Down syndrome. <i>Brain</i> , 2014, 137, 2556-2563.	3.7	87
77	A multisite trial of atomoxetine and parent training in children with autism spectrum disorders: Rationale and design challenges. <i>Research in Autism Spectrum Disorders</i> , 2014, 8, 899-907.	0.8	10
78	Use of a Direct Observational Measure in a Trial of Risperidone and Parent Training in Children with Pervasive Developmental Disorders. <i>Journal of Developmental and Physical Disabilities</i> , 2013, 25, 355-371.	1.0	16
79	Toward an exportable parent training program for disruptive behaviors in autism spectrum disorder. <i>Neuropsychiatry</i> , 2013, 3, 169-180.	0.4	33
80	Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B. <i>Alzheimer's and Dementia</i> , 2012, 8, 496-501.	0.4	116
81	Safety and Efficacy of Donepezil in Children and Adolescents with Autism: Neuropsychological Measures. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2011, 21, 43-50.	0.7	51
82	Effects of Gluten Free / Casein Free Diet in Young Children with Autism: A Pilot Study. <i>Journal of Developmental and Physical Disabilities</i> , 2011, 23, 213-225.	1.0	63
83	Psychopharmacological treatment of ADHD symptoms in children with autism spectrum disorder. <i>International Journal of Adolescent Medicine and Health</i> , 2011, 23, 167-73.	0.6	21
84	Polyunsaturated Fatty Acid Supplementation in Young Children with Autism. <i>Journal of Developmental and Physical Disabilities</i> , 2010, 22, 1-10.	1.0	27
85	Standardised Observation Analogue Procedure (SOAP) for assessing parent and child behaviours in clinical trials. <i>Journal of Intellectual and Developmental Disability</i> , 2009, 34, 230-238.	1.1	14
86	Trial Design Challenges When Combining Medication and Parent Training in Children with Pervasive Developmental Disorders. <i>Journal of Autism and Developmental Disorders</i> , 2009, 39, 720-729.	1.7	35
87	A Double-Blind, Placebo-Controlled Trial of Oral Human Immunoglobulin for Gastrointestinal Dysfunction in Children with Autistic Disorder. <i>Journal of Autism and Developmental Disorders</i> , 2009, 39, 796-805.	1.7	37
88	Medication and Parent Training in Children With Pervasive Developmental Disorders and Serious Behavior Problems: Results From a Randomized Clinical Trial. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2009, 48, 1143-1154.	0.3	279
89	Eating Habits and Dietary Status in Young Children with Autism. <i>Journal of Developmental and Physical Disabilities</i> , 2008, 20, 437-448.	1.0	73
90	Methylphenidate and Play Skills in Children with Intellectual Disability and ADHD. <i>Journal of Mental Health Research in Intellectual Disabilities</i> , 2008, 2, 1-10.	1.3	3

#	ARTICLE	IF	CITATIONS
91	Guanfacine in Children with Autism and/or Intellectual Disabilities. <i>Journal of Developmental and Behavioral Pediatrics</i> , 2008, 29, 303-308.	0.6	112
92	Development of a parent training program for children with pervasive developmental disorders. <i>Behavioral Interventions</i> , 2007, 22, 201-221.	0.8	61
93	Preschoolers with Developmental Disabilities: A Comparison of an ADHD and a NonADHD Group. <i>Journal of Developmental and Physical Disabilities</i> , 2007, 19, 579-592.	1.0	3
94	Open-Label, Prospective Trial of Olanzapine in Adolescents With Subaverage Intelligence and Disruptive Behavioral Disorders. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2006, 45, 928-935.	0.3	30
95	Practitioner Review: Psychopharmacology in children and adolescents with mental retardation. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2006, 47, 871-882.	3.1	80
96	Reactions to "Ethical challenges and complexities of including people with intellectual disability as participants in research" by Dr Teresa Iacono. <i>Journal of Intellectual and Developmental Disability</i> , 2006, 31, 180-182.	1.1	23
97	Secretin in Children with Autistic Disorder: A Double-Blind, Placebo-Controlled Trial. <i>Journal of Developmental and Physical Disabilities</i> , 2005, 17, 95-107.	1.0	7
98	Retrospective Assessment of Atomoxetine in Children and Adolescents with Pervasive Developmental Disorders. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2005, 15, 325-330.	0.7	61
99	Pharmacotherapy in Autism and Related Disorders.. <i>School Psychology Quarterly</i> , 2005, 20, 155-171.	2.4	17
100	A Retrospective Open Trial of Adjunctive Donepezil in Children and Adolescents with Autistic Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2002, 12, 237-241.	0.7	98
101	Double-Blind, Placebo-Controlled Study of Amantadine Hydrochloride in the Treatment of Children With Autistic Disorder. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2001, 40, 658-665.	0.3	181
102	Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. <i>Journal of Autism and Developmental Disorders</i> , 2000, 30, 245-255.	1.7	290
103	Efficacy of Methylphenidate Among Preschool Children With Developmental Disabilities and ADHD. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 1999, 38, 805-812.	0.3	116
104	A playroom observation procedure to assess children with mental retardation and ADHD. <i>Journal of Abnormal Child Psychology</i> , 1998, 26, 269-277.	3.5	31
105	Naltrexone in Young Autistic Children: Replication Study and Learning Measures. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 1997, 36, 1570-1578.	0.3	53
106	Long-term follow-up of children with mental retardation/borderline intellectual functioning and ADHD. <i>Journal of Abnormal Child Psychology</i> , 1997, 25, 287-295.	3.5	55
107	Naltrexone in Young Autistic Children. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 1997, 36, 1570-1578.	0.3	40
108	Stimulant medication effects on learning in children with mental retardation and ADHD. <i>Journal of Developmental and Physical Disabilities</i> , 1996, 8, 335-346.	1.0	16



#	ARTICLE	IF	CITATIONS
109	Methylphenidate in children with mental retardation and ADHD: Effects on independent play and academic functioning. <i>Journal of Developmental and Physical Disabilities</i> , 1995, 7, 91-103.	1.0	14
110	Naltrexone in Young Autistic Children: A Double-Blind, Placebo-Controlled Crossover Study. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 1995, 34, 223-231.	0.3	113
111	Classroom behavior and children with mental retardation: Comparison of children with and without ADHD. <i>Journal of Abnormal Child Psychology</i> , 1994, 22, 267-280.	3.5	23
112	Prediction of Response to Methylphenidate among Children with ADHD and Mental Retardation. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 1994, 33, 1185-1193.	0.3	53
113	Pharmacotherapy in Mental Retardation and Autism. <i>School Psychology Review</i> , 1993, 22, 162-183.	1.8	9
114	Using guided compliance versus time out to promote child compliance: A preliminary comparative analysis in an analogue context. <i>Research in Developmental Disabilities</i> , 1992, 13, 157-170.	1.2	24
115	Effects and Noneffects of Methylphenidate in Children with Mental Retardation and ADHD. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 1992, 31, 455-461.	0.3	85
116	Mental Retardation and ADHD!. <i>Pediatrics</i> , 1992, 89, 351-352.	1.0	0
117	Adverse Side Effects of Methylphenidate among Mentally Retarded Children with ADHD. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 1991, 30, 241-245.	0.3	114
118	CSF Biomarkers in Down Syndrome and Autosomal Dominant Alzheimer Disease. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
119	Physical activity and physical and mental health in <scp>middle-aged</scp> adults with Down syndrome. <i>Journal of Policy and Practice in Intellectual Disabilities</i> , 0, , .	1.7	0